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FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER:  
AN EXPERT UPDATE
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Summary
Ovarian cancer is the fifth most common cause of death among malignant diseases in women in Europe. The standard 
treatment is cytoreductive surgery, followed by platinum-taxane based chemotherapy. In patients with advanced disease, a 
valid option is a neoadjuvant chemotherapy followed by interval debulking surgery. Despite the progress in primary treat-
ment, almost 70% of the patients relapse. There is a significant need for better first-line treatment to avoid or delay relapse 
and improve ovarian cancer outcomes. The most significant change involves the changes in the treatment schedule and new 
drugs in first-line chemotherapy. Bevacizumab is approved in first-line treatment combined with carboplatin and paclitaxel 
as it improves progression-free survival (PFS) in patients with a higher risk of recurrence. After achieving the response to 
first-line chemotherapy, maintenance therapy with poly-adenosine-diphosphate-ribose-polymerase (PARP) inhibitors pro-
longs PFS in patients with homologous recombination deficiency (HRD). Patients with BRCA mutations obtain the most 
significant benefit.
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Ovarian cancer is the most lethal gynecologic 
cancer. Primary debulking surgery, followed by a 
combination of platinum-paclitaxel-based chemo-
therapy, is cur rently considered as the standard of 
care for advanced epithelial ovarian cancer (1). 
The introductions of weekly paclitaxel therapy 
and intraperitoneal chemotherapy are standard 
treatment options for patients with ovarian can-
cer, except for the disease’s early stage (1). The in-
troductions of weekly paclitaxel and intraperito-
neal chemotherapy are recognized alternatives 
considered acceptable as primary treatment (2,3). 
In patients with considerable and aggressive tu-
mor dissemination or in patients with advanced 
disease where R0 resection cannot be achieved, an 
alternative treatment strategy is neoadjuvant che-
motherapy with delayed surgery (i.e., interval de-
bulking surgery). After neoadjuvant chemothera-
py, delayed cytoreductive surgery is not inferior 
to primary debulking surgery, as shown in ran-
domized, controlled trials (4,5).
Despite the progress achieved in the last de-
cades, almost 70% of the patients experience a re-
lapse. The most significant breakthrough in the 
last decades was the addition of new drugs (6).
The targeted therapy is presumably less toxic 
than polychemotherapy and neo-angiogenesisis 
widespread in solid-tumor growth and metasta-
sis. Therefore research has been concentrated on 
antiangiogenetic drugs. The rationale to use an 
antiangio genic treatment in cancer is the presence 
of hypoxia in cancer tissue. The reduction of 
 oxygen promotes vascular endothelial growth 
 factor (VEGF) receptors on the endothelial cells. 
Subsequently, the binding of circulating vascular 
endothelial growth factor with the receptor leads 




Bevacizumab, a humanized monoclonal IgG 
antibody that targets vascular endothelial growth 
factor receptor, has been one of the first and most 
investigated antiangiogenetic drugs. It also dem-
onstrated efficacy in ovarian cancer. This inhibi-
tion leads to a reduction of neo-angiogenesis and 
an increase in vascular permeability. Consequent-
ly, a higher dose of chemotherapeutic agents is 
released, finally resulting in tumor endothelial cells 
apoptosis(7).
Bevacizumab is approved 2011 by the Euro-
pean Medicines Agency (EMA) and 2018 by the 
Food and Drug Administration (FDA) for the first-
line treatment in patients with ovarian cancer, fal-
lopian tube, and primary peritoneal cancers stage 
III and IV in combination with carboplatin and 
paclitaxel. The approval is based on the results of 
a multicenter, phase III trial. The Gynecologic On-
cology Group trial (GOG-0218) involved 1873 
women with stage III/IV ovarian cancer. After pri-
mary debulking surgery, patients were random-
ized to receive the standard treatment (carboplat-
in and paclitaxel - group A) or add Bevacizumab 
from cycles 2 through 6, followed by placebo B, or 
Bevacizumab from cycles 2 through 22 - group C). 
Bevacizumab was administered at a dosage of 15 
mg/kg every three weeks. The study’s primary 
endpoint was progression-free survival (PFS), with 
overall survival (OS) as a secondary endpoint. The 
median PFS was 10.3, 11.2, and 14.1 months in 
group A, group B, and group C, respectively (HR 
for group B compared with the control group was 
0.717; P=0.001) (8). The final data for OS presented 
at the 2018 American Society of Clinical Oncology 
(ASCO) did not demonstrate a difference among 
the groups in terms of OS (HR for group B vs. 
group A was 1.06; P=0.34, and for group C vs. 
group A was 0.96; P=0.53) (9).
The International Collaborative Ovarian 
Neoplasm Trial 7 (ICON-7) was another phase III 
randomized trial enroll ing 1528 patients with 
FIGO stage I–IIA clear-cell/grade 3 or FIGO stage 
III/IV epithelial ovarian cancer, primary peritone-
al or fallopian tube cancer, to receive six cycles of 
3-weekly carboplatin and paclitaxel with or with-
out Bevacizumab (7.5 mg/kg) for 12 months. The 
primary endpoint was PFS. The median PFS was 
17.4 months for the control group vs. 19.8 months 
for the bevacizumab group (P=0.004) (10). Similar 
to the GOG-0218 study, no differences in the OS 
rate were reported after 49 months of follow-up 
(44.6 vs. 45.5 months for the control and bevaci-
zumab groups, respectively, P=0.85) (11). In both 
the studies, ICON-7, and GOG-0218, high-risk pa-
tients seem to benefit the most from the addition 
of Bevacizumab. The “higher risk” was defined as 
a patient with a FIGO stage III tumor, suboptimal-
ly debulked (residual disease) or stage IV (8-11).
In both GOG-0218 and ICON-7 trials, Bevaci-
zumab was given concurrently with the tradition-
al 3-weekly carboplatin/ paclitaxel chemotherapy. 
However, the Japanese Gynecologic Oncology 
Group (JGOG), demonstrated a better prognosis 
in patients treated with a dose-dense strategy (car-
boplatin 3-weekly and paclitaxel weekly vs. car-
boplatin and paclitaxel 3-weekly). This opened 
the question of which schedule is better. Sub-
sequently, the Multicenter Italian Trials in Ovari-
an Cancer (MITO) studied another schedule of 
treatment. In the MITO-7 trial, carboplatin (AUC 
2) plus paclitaxel (60 mg/m2) adminis trated both 
weekly was compared with the standard treat-
ment. Comparable results in terms of PFS with 
less adverse events were found in the weekly 
schedule (PFS was 18.8 vs 16.5 months, P=0.18) 
(12). The phase III trial ICON-8 was conducted to 
investigate the weekly chemotherapy in the Euro-
pean population. At the European Society for 
Medical Oncology (ESMO) Virtual Congress 2020, 
final analysis of ICON-8 confirmed that weekly 
dose-dense chemotherapy with paclitaxel or pa-
clitaxel/carboplatin could be successfully and 
safely administered as first-line treatment for epi-
thelial ovarian cancer but without OS or PFS ben-
efits over standard 3-weekly chemotherapy (13).
According to the EMA and FDA approval, 
the current administration of Bevacizumab is up 
to 22 cycles (15 months). In the GOG-0218, Bevaci-
zumab was administrated for 15 months, in the 
ICON-7 for 12 months. The ROSiA study, a single-
arm phase 3B study was designed, to evaluate the 
efficacy and safety of prolonging Bevacizumab be-
yond 15 months. According to the acceptable tox-
icity profile, and the longest reported PFS for 
frontline bevacizumab-containing therapy, treat-
ment prolongation with Bevacizumab seems to be 
feasible (14). The conclusion could be drawn only 
when the final results of AGO OVAR17, a phase III 
randomized controlled trial comparing 15 vs. 30 
months of bevacizumab therapy, will be available 
in 2021 (15) (Table 1).
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Bevacizumab is investigated in neoadjuvant 
treatment along with chemotherapy. ANTHALYA 
trial was a phase II multicenter randomized trial 
aimed to evaluate the safety and efficacy of Beva-
cizumab in a neoadjuvant setting. Patients initially 
received four cycles of neoadjuvant 3-weekly car-
boplatin-paclitaxel chemotherapy with or without 
three cycles of Bevacizumab followed by interval 
debulking surgery. After surgery, adjuvant che-
motherapy was administrated, reintroducing Bev-
acizumab at cycle six and maintained for at least 
26 cycles. The complete resection rate (CRR) was 
higher in the group with Bevacizumab (85.5%) 
with an acceptable toxicity profile (16). These data 
were confirmed in a more recent phase IV study, 
the MITO16A-Mango OV2A, a trial designed to 
find a prognostic factor to individualize the thera-
py with Bevacizumab (17). Although Bevacizum-
ab has been investigated in a few neoadjuvant 
studies, further studies are necessary to draw de-
finitive conclusions (Table 2).
Angiogenesis plays a vital role in ovarian 
cancer, but it is still not clear in which category of 
patients the addition of antiangiogenic therapy 
could improve the prognosis. In the ICON-7 
study, molecular analysis was done. Four molecu-
lar subtypes were found: differenti ated (20%), im-
munoreactive (34%), mesenchymal (19%), and 
proliferative (27%). Patients with mesenchy mal 
and proliferative tumors had a worse prognosis 
compared to the differentiated and immunoreac-
tive subgroups (18). Data from randomized trials 
are still pending, and researchers are looking for 
biological factors to identify women who could 
most benefit from the addition of bevacizumab 
therapy.
Nevertheless, limitations of paclitaxel-plati-
num-based chemotherapy with bevacizumab 
treatment strategies lie in the fact that median PFS 
after first-line therapy is a maximum of 18 months 
and progressive disease develops in more than 
70% of patients within three years. Therefore, 
Table 1.
Bevacizumab in first-line treatment
Study Patients Study arm (S) Control arm (C) Results
GOG-02188,9 Stage III-IV S1: Carboplatin + paclitaxel q3w  
+ bevacizumab 15 mg/kg q3w  
from cycle 2 through 6
S2: Carboplatin + paclitaxel q3w  
+ bevacizumab 15 mg/kg q3w  
from cycle 2 through 22 for 15 months
Carboplatin  
+ paclitaxel q3w 
+ placebo
PFS 11,2 (S1) vs 14,1 (S2)  
vs 10,3 months (C);
HR 0.717;
P=0.34
OS 38,7 (A) vs 39,7 (B)  
vs 39,3 months (C);
HR 0.96;
P=0.53
ICON-710,11 Stage I-II G3  
or clear cell  
or stage IIB-IV
Carboplatin + paclitaxel q3w  
+ bevacizumab 7,5 mg/kg q3w  
for 12 months
Carboplatin  
+ paclitaxel q3w 
PFS 19,8 ( S) vs 17,4 months (C);
P=0.004
OS 45,5 (S) vs 44,6 months (C)
P=0.85
ROSiA14 Stage IIB-IV  
or grade 3 stage 
I-IIA
Carboplatin + paclitaxel q3w  
+ bevacizumab 7,5 or 15 mk/kg q3w  
for 24 months
Not available PFS 25,5 months (S)
Table 2.
Bevacizumab in neoadjuvant treatment
Study Patients Study arm (S) Control arm (C) Results
ANTHALYA16 Stage IIIC-IV NACT: Carboplatin + paclitaxel q3w 1-4 cycle  
+ bevacizumab 15 mg/kg q3w 1-3 cycle
ADJ: Carboplatin + paclitaxel q3w 5-8 cycle  
+ bevacizumab 15 mg/kg q3w 6-26 cycle
NACT: Carboplatin + paclitaxel 
q3w 1-4 cycle
ADJ: Carboplatin + paclitaxel 
q3w 5-8 cycle + bevacizumab 
15 mg/kg q3w 6-26 cycle




Stage IIIB-IV NACT: Carboplatin + paclitaxel q3w  
+ bevacizumab 15 mg/kg q3w
ADJ: Carboplatin + paclitaxel q3w cxcle  
+ bevacizumab 15 mg/kg q3w up to  
a max 16 additional cycles
Not available CRR 63,5%
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there is a significant need for better frontline treat-
ment to avoid or delay relapse and improve wom-
en’s outcomes with ovarian cancer. The ideal sce-
nario is to develop a treatment that would demon-
strate a significant benefit in PFS during first-line 
treatment. The difference between treatments 
would continue to be upheld during subsequent 
treatments, leading ultimately to a difference in 
OS, which is rarely seen, partly because of the ex-
tended post-progression survival in ovarian can-
cer, with multiple subsequent treatments and, in 
some situations, crossover to the experimental 
therapy (19). As in the trial of maintenance olapa-
rib therapy in platinum-sensitive recurrent ovari-
an cancer (Study19), there were considerable dif-
ferences in PFS but much smaller OS (20). An ex-
ploratory analysis removing patients where 
crossover occurred showed a significant differ-
ence in OS with maintenance olaparib (21). Addi-
tionally, because of an extended post-progression 
survival, OS endpoint often becomes available 
several years after recruitment to the trial was 
completed. As there is academic and regulatory 
pressure to analyze results early, PFS has become 
a primary endpoint for many first-line trials (19).
Recently, a significant breakthrough hap-
pened with the introduction of Poly (ADP-ribose) 
polymerase (PARP) inhibitors. They inhibit and 
trap PARP on deoxyribonucleic acid (DNA) at sin-
gle-strand break sites. This prevents the repair of 
these breaks and generates double-strand breaks 
that cannot be repaired accurately in tumors with 
homologous-recombination deficiency (HRD), 
causing tumor cell death (synthetic lethality). Ap-
proximately 20-30% of ovarian carcinomas have 
germline or somatic BRCA1 or BRCA2 mutations. 
HRD is not limited to tumors with BRCA muta-
tions and is present in approximately 50% of high-
grade serous ovarian tumors. These alterations 
increase tumor susceptibility to agents, including 
platinum and PARP inhibitors (22).
The efficacy of PARP inhibitors (olaparib, ni-
raparib, rucaparib) has been confirmed in several 
clinical studies phase III (SOLO2, NOVA, and 
 ARIEL3) in patients with platinum-sensitive re-
lapse (23,24,25). The next step was to examine 
their efficacy and tolerability in the first-line treat-
ment after responding to platinum-paclitaxel-
based chemotherapy.
The SOLO1 trial evaluated the efficacy of 
maintenance therapy with PARP inhibitor olapar-
ib in patients with newly diagnosed advanced 
ovarian cancers whose tumors had germline or so-
matic BRCA1/2 mutations. This study enrolled 
391 patients with stage III (85%) and stage IV 
(15%). The majority of them had no residual dis-
ease after cytoreductive surgery, and complete ra-
diological response to chemotherapy was con-
firmed in 85% of patients. They were randomized 
to receive olaparib 300 mg twice daily versus pla-
cebo until radiological disease progression, unac-
ceptable toxicity or for up to 2 years for a complete 
response. The primary endpoint was PFS. Results 
were presented at the ESMO 2018 meeting. PARP 
inhibitor olaparib provided a substantial progres-
sion-free survival benefit as maintenance mono-
therapy in a select group of patients with newly 
diagnosed advanced ovarian cancer whose tu-
mors had a BRCA mutation and had a complete or 
partial clinical response after platinum-based che-
motherapy. The median PFS was not reached in 
the olaparib arm vs. 13,8 months in the placebo 
arm. After three years, 60% of patients in the 
olaparib arm were without disease progression 
vs. 27% in the placebo arm (HR 0.30; P<0.001) (26). 
After two years, at the ESMO Virtual Congress 
2020, investigators presented data from the SOLO1 
trial after the most extensive follow-up for any 
PARP inhibitor in the first-line setting. Almost half 
of the patients were progression-free vs. 20% in 
the placebo arm (HR 0.33), and more than half of 
women in complete response at baseline who re-
ceived maintenance olaparib for two years re-
mained free from relapse five years later (HR 0.37) 
(27). The SOLO1 study results are consistent with 
Study19 and SOLO2 trials investigating olaparib 
in recurrent ovarian cancer (20, 23, 28).
At the ESMO 2019 meeting, three new clinical 
trials phase III with three different PARP inhibitors 
and a different way of incorporating in first-line 
treatment showed substantial benefit when used in 
patients with newly diagnosed ovarian cancer. Ni-
raparib, olaparib with Bevacizumab, and veliparib 
clinically and statistically significant prolonged 
PFS after first-line platinum-based chemotherapy.
PRIMA trial evaluated efficacy and safety of 
niraparib maintenance therapy after response to 
platinum-based chemotherapy in patients with 
newly diagnosed advanced ovarian cancer at high 
risk for relapse (stage III with visible residual dis-
ease after primary debulking or inoperable stage 
III, stage IV, and those who had received neoadju-
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vant chemotherapy). Niraparib significantly im-
proved PFS when compared with placebo, regard-
less of the presence or absence of HRD. In the 
overall population, the median PFS was 13,8 vs. 
8,2 months (HR 0.62, P<0.001). The benefit from 
niraparib was even more significant in the sub-
group of 51% of patients with HRD (mPFS 21,9 vs. 
10,4 months, HR 0.43). In patients with HRD pro-
ficient tumors, niraparib monotherapy provides 
clinically significant benefits too. The most com-
mon adverse events of grade 3 or higher were ane-
mia, thrombocytopenia, and neutropenia (29). The 
PRIMA study results are consistent with NOVA 
and QUADRA trials investigating niraparib in re-
current ovarian cancer (30,31).
According to preclinical data, hypoxia-in-
duced by an antiangiogenic treatment can induce, 
or at least increase HRD, which means that Bevaci-
zumab may increase olaparib activity in patients 
HRD-positive tumors and, in particular, patients 
with HRD-positive tumors without a BRCA muta-
tion. The addition of an antiangiogenic agent to a 
PARP inhibitor in phase 2 studies involving pa-
tients with relapsed platinum-sensitive ovarian 
cancer resulted in longer PFS than the use of a 
PARP inhibitor alone (32,33). In the phase III 
PAOLA-1 trial, investigators evaluated mainte-
nance therapy with olaparib compared with pla-
cebo in patients with newly diagnosed advanced 
ovarian cancer receiving chemotherapy plus 
 Bevacizumab followed by Bevacizumab. The 
PAOLA-1 population was representative of the 
majority of patients with advanced ovarian cancer 
because the patient selection was not restricted 
based on the surgical outcome or BRCA mutation 
status. Maintenance therapy with olaparib and 
Bevacizumab vs. Bevacizumab significantly im-
proved mPFS (22,1 vs. 16,6 months; HR 0.59, 
P<0.0001). The magnitude benefit was most re-
markable for those whose tumors had BRCA mu-
tations (mPFS 37,1 vs. 21,7 months; HR 0.31). Pa-
tients with HRD negative tumors did not benefit in 
PFS when they received olaparib with Bevacizum-
ab compared to Bevacizumab only. Olaparib did 
not impact bevacizumab tolerability and quality of 
life (34). Following the SOLO1 trial and PAOLA-1 
study results, it is difficult to define the real impact 
of bevacizumab addition in the frontline mainte-
nance strategy. For now, it looks like monotherapy 
is the preferred option due to less toxicity (patient 
and financial) and similar efficacy.
Another approach with concomitant ordina-
tion of PARP inhibitor and chemotherapy was 
evaluated in the VELIA trial. This trial evaluated 
the safety and efficacy of veliparib concurrent with 
chemotherapy. It continued as maintenance in pre-
viously untreated patients with advanced high-
grade serous ovarian carcinoma regardless of bio-
marker, surgery choice, or paclitaxel regimen. In 
the intention-to-treat population, mPFS was 23,5 
vs 17,3 months (HR 0.68, P<0.001), in the BRCAm 
cohort 34,7 vs 22 months, (HR 0.44, P<0.001) and in 
HRD cohort 31,9 vs 20,5 months (HR 0.57, P<0.001). 
Veliparib given concurrently with chemotherapy 
only did not benefit in PFS. The trial design did not 
include an arm with veliparib maintenance only 
and therefore did not prospectively address the 
relative contribution of maintenance therapy with 
veliparib. This PARP inhibitor led to a higher inci-
dence of anemia and thrombocytopenia, combined 
with chemotherapy (35).
The use of PARP inhibitors (olaparib only, 
olaparib concurrent with Bevacizumab, niraparib 
only, veliparib concurrent with chemotherapy fol-
lowed by maintenance) as first-line maintenance 
therapy for advanced ovarian cancer improves 
PFS, according to four phase III studies (36). The 
effectiveness of PARP inhibitors has been evalu-
ated in three different biological subtypes of ovar-
ian cancer. Patients with BRCA mutated tumors 
obtain the most significant benefit in PFS. The 
HRD-positive BRCA wild type can be considered 
a new clinical population that showed a similar 
benefit compared to the BRCA-mutated subgroup 
from the addition of a PARP inhibitor.
Conversely, the HRD-negative population 
achieved a modest survival advantage from ni-
raparib monotherapy after a response to first-line 
chemotherapy. Since no comparison with the Bev-
acizumab was performed in the PRIMA trial, for 
HRD negative patients, niraparib, or bevacizumab 
maintenance could be both valid options (37). 
PARP inhibitors have an acceptable toxicity pro-
file and ensure a good quality of life (36, 37). How-
ever, several ongoing studies of new combination 
strategies (NCT03737643 – phase III trial with 
platinum-based chemotherapy, durvalumab, bev-
acizumab and olaparib , NCT03602859 – phase III 
trial with platinum-based chemotherapy, dostar-
limab and niraparib) could clearly define the role 
of PARP inhibitors as maintenance therapy in the 
first-line setting of ovarian cancers. The magni-
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tude of benefit varies widely among subgroups, 
highlighting the need to identify specific biologi-
cal subtypes in clinical practice. In this regard, it is 
necessary to introduce HRD testing, which is cur-
rently expensive, time-consuming, and not repro-
ducible in standard laboratories. Finally, validat-
ed biomarkers to quantify the HRD status in each 
patient are warranted to identify the subgroup of 
patients who derived more benefit from PARP in-
hibitors (38) (Table 3).
In conclusion, the first-line treatment for ad-
vanced ovarian cancer can be summarized through 
the three steps. The first step involves selecting 
patients based on the extend of the disease to ini-
tially operable with presumed R0 resection and 
inoperable disease, followed by neoadjuvant treat-
ment. The second step implies systemic treatment 
with platinum-based chemotherapy strengthened 
by bevacizumab and/or PARP inhibitors, depend-
ing on the risk of recurrence and molecular/genet-
ic changes. The third step represents new treat-
ment options, i.e., new drugs or combinations of 
existing drugs. All three steps are based on the 
personalized treatment that should improve ovar-
ian cancer patients’ outcomes.
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Sažetak
PRVOLINIJSKO LIJEČENJE UZNAPREDOVALOG RAKA JAJNIKA: NOVOSTI
B. Petrić Miše
Rak jajnika je peti najčešći uzrok smrti među zloćudnim bolestima kod žena u Europi. Standardni način liječenja je 
primarna citoredukcija praćena kemoterapijom temeljenom na platini i taksanima. Kod bolesnica s uznapredovalom bolesti 
jedna od opcija liječenja je neoadjuvantna kemoterapija s intervalnom citoredukcijom. Unatoč napretku u liječenju, gotovo 
70% bolesnica razvije povrat bolesti. Postoji značajna potreba za poboljšanjem prvolinijskog liječenja s ciljem izbjegavanja ili 
odgađanja povrata bolesti i poboljšanja ishoda liječenja bolesnica s rakom jajnika. Najvažnija promjena uključuje izmjene u 
načinu primjene lijekova i dodavanje novih lijekova prvolinijskoj kemoterapiji. Bevacizumab je odobren u prvolinijskom 
liječenju u kombinaciji s karboplatinom i paklitakselom zbog poboljšanja preživljenja do napredovanja bolesti (PFS) kod 
bolesnica s povećanim rizikom od recidiva. Terapija održavanja PARP inhibitorima, nakon odgovora na prvolinijsku kemo-
terapiju, produljuje PFS kod bolesnica s poremećajem u sustavu popravka dvostrukih lomova deoksiribonukleinske kiseline 
homolognom rekombinacijom. Najveću korist imaju bolesnice s BRCA mutacijama.
KLJUČNE LIJEČI: karcinom jajnika, kemoterapija, bevacizumab, PARP inhibitori
